Toll-Free 8259 00 1000

Meet Yurpeak®

The Starter Kit

You and your doctor made the choice that Yurpeak® is right for you. This starter kit gives you details about Yurpeak and explains what to expect.

All of this will help you start off in the right direction during your first days of using Yurpeak®.

Always consult your doctor to determine if Yurpeak® is the right choice for your weight management goals.

What is Yurpeak® ?1

Yurpeak® is a prescription medication indicated for weight management in adults with obesity or overweight. This includes individuals with a body mass index (BMI) of ≥ 30 or those with a BMI of ≥ 27, who also have weight-related complications, such as Type 2 diabetes, Hypertension, Cardiovascular Disease or Obstructive Sleep Apnea.

How it works? 1

Yurpeak® works by mimicking the effects of natural hormones produced in the gut in response to ingestion of food that can help regulate appetite and food intake, leading to reduced hunger and increased feelings of fullness. Clinical studies have shown that Yurpeak® can lead to significant weight loss when used alongside a reduced calorie diet and increased physical activity.

Administered as a weekly injection, Yurpeak® provides a convenient option for individuals seeking to achieve and maintain a healthier weight.

Yurpeak® may help you reach your weight loss goals by:

Reducing your appetite & food intake1
Reducing your cravings for sweets & other high-carb foods appetite & food intake2
Decreasing your body weight1
Lowering your body fat1
References 1. Tirzepatide once weekly India Prescribing Information | March 2025. 2. Martin CK, Ravussin E, Sanchez-Delgado G, et al. 128-OR: the effect of tirzepatide during weight loss on food intake, appetite, food preference, and food craving in people with obesity. Diabetes. 2023;72(suppl1):128-OR. doi:10.2337/db23-128-OR.
Ready to get started?
GETTING STARTED
Disclaimers: This initiative is solely for patient support. It has been created with an intention to provide, assistance and support to patients & NOT intended towards product promotion, NOR advertisement of any health care professionals or doctors.  Patients should be advised to consult and seek medical advice from their concerned doctor/ health care professional before starting any treatment/medicine/ diet plan. Any advice regarding the management of any medical condition is completely at the discretion of their consulting physician/doctor (Registered Medical Practitioner). Cipla limited makes no representations as to the efficacy, accuracy, appropriateness, or suitability of any specific tests, products, procedures, treatments, services, opinions, healthcare providers or other information that may be shared through this screening/program/activity. Cipla shall not be responsible for any direct, indirect, consequential or other damages arising therefrom. No personal data is being collected, stored, or processed by Cipla as a part of this initiative. Yurpeak®, KwikPen® and Lilly are registered trademark of Eli Lilly & Company, promoted and distributed by Cipla in India. The “CIPLA” mark and logo are the sole and intellectual property of Cipla Limited. Nothing on this website should be construed as giving medical advice or making recommendations regarding any health-related decision or action. You should consult a doctor or other qualified healthcare professional regarding any questions about your health or before making any treatment-related decisions. The contents of this site are not intended to substitute the medical judgment of your treating physicians. This website is intended for people over 18 years of age. This website is intended for the sole use of registered health care providers and patients prescribed with Yurpeak (tirzepatide) on their physician's advice. Yurpeak and its delivery device base are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates. Yurpeak is available by prescription only. To be sold by retail under prescription of Endocrinologist or Internal Medicine specialists only. For adverse events and safety reporting, please reach out to: drugsafety@cipla.com or report to Cipla Ltd. on 18002577779 For any additional information related to Lilly products, please reach out to: queries_in-medinfo@lilly.com.